negative effects of glp 1 agonists Managing Side GLP-1 Receptor – Transformation Weight Control Gastrointestinal (GI) Side Effects of

A nutrition and lifestyle-focused shared medical appointment in a resource-challenged community setting: a mixed-methods study

In Graves disease, where extrathyroidal manifestations are mediated by TSHR/IGF-1R-expressing fibroblasts, studies could test GLP-1RAs as adjuncts to antithyroid drugs or biologics (for example, alongside IGF-1R blockade for orbitopathy) to reduce systemic inflammation and metabolic drivers without compromising disease control [19,25,67]

However, given the neutral effect of GLP-1 RAs on surrogate HF outcomes in HFrEF and a potentially increased risk of arrhythmias and HF-related hospitalisations, conducting further large-scale trials in the HFrEF cohort seems complicated

Although the use of DPP-4 inhibitors is associated with increased bone formation, their effects are more associated with mechanisms related to the suppression of bone resorption

Small-molecule GLP-1RA litigation over the coming decade will likely generate more numerous, more independently contested patent challenges than peptide GLP-1RA litigation has

Several GLP-1 agonists are part of this program, including: Exenatide: Results from a large, phase 2 trial in 2017 suggested that exenatide may slow Parkinsons progression